Insider Selling: TransMedics Group, Inc. (NASDAQ:TMDX) Director Sells 6,750 Shares of Stock

TransMedics Group, Inc. (NASDAQ:TMDX) Director Edward M. Basile sold 6,750 shares of the company’s stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $83.55, for a total value of $563,962.50. Following the completion of the transaction, the director now directly owns 732 shares in the company, valued at $61,158.60. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

TransMedics Group Stock Performance

Shares of TMDX stock traded down $0.85 during mid-day trading on Thursday, reaching $85.50. The stock had a trading volume of 1,118,768 shares, compared to its average volume of 949,247. The business’s fifty day moving average is $135.29 and its 200-day moving average is $139.58. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. The firm has a market cap of $2.87 billion, a price-to-earnings ratio of 91.86 and a beta of 2.08. TransMedics Group, Inc. has a 1-year low of $55.29 and a 1-year high of $177.37.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings data on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). The firm had revenue of $108.76 million during the quarter, compared to analyst estimates of $115.00 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The firm’s revenue for the quarter was up 63.7% on a year-over-year basis. During the same period in the prior year, the company posted ($0.12) earnings per share. On average, research analysts forecast that TransMedics Group, Inc. will post 1.08 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of TMDX. Vanguard Group Inc. grew its holdings in TransMedics Group by 1.3% in the first quarter. Vanguard Group Inc. now owns 1,889,094 shares of the company’s stock valued at $139,680,000 after purchasing an additional 23,979 shares during the period. Driehaus Capital Management LLC lifted its position in TransMedics Group by 15.8% during the second quarter. Driehaus Capital Management LLC now owns 1,486,073 shares of the company’s stock worth $223,832,000 after buying an additional 202,867 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its position in TransMedics Group by 5.3% during the third quarter. Allspring Global Investments Holdings LLC now owns 599,116 shares of the company’s stock worth $94,061,000 after buying an additional 30,092 shares in the last quarter. Vaughan Nelson Investment Management L.P. raised its position in TransMedics Group by 24.3% in the third quarter. Vaughan Nelson Investment Management L.P. now owns 329,010 shares of the company’s stock valued at $51,654,000 after purchasing an additional 64,360 shares during the period. Finally, Price T Rowe Associates Inc. MD raised its position in TransMedics Group by 8.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 297,324 shares of the company’s stock valued at $21,985,000 after purchasing an additional 22,223 shares during the period. 99.67% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have recently issued reports on TMDX. Oppenheimer dropped their price target on TransMedics Group from $200.00 to $125.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 29th. Stephens upped their price objective on TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. Piper Sandler restated an “overweight” rating and set a $180.00 price objective on shares of TransMedics Group in a research note on Tuesday, October 29th. Baird R W upgraded TransMedics Group to a “strong-buy” rating in a research note on Tuesday, September 24th. Finally, Robert W. Baird decreased their price objective on TransMedics Group from $200.00 to $150.00 and set an “outperform” rating for the company in a research note on Tuesday, October 29th. One analyst has rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Buy” and an average target price of $144.80.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.